Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Xeris Biopharma Holdings, Inc.

NASDAQ: XERS · Life Sciences · 12 alerts · CIK 1867096

Share price
$16.70Close, Nov 16
Market cap
$3.05B
Shares outstanding
182.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xeris Biopharma Holdings, Inc. filings on SEC EDGAR ↗

4:32 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock

Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).

Value
$312K
Shares
25,000
Price
$12.49
Holding change
-1.6%
Trade date
Nov 5, 2026
4:10 PM ET 10-Q
Financial Results ▶ Call

Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY

Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.

Key figure
Net income $11.3M · +1718.0% YoY
7:14 AM ET 8-K
Financial Results

Xeris Biopharma Holdings Financial Results

Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.

“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”

John Shannon, Chairman and Chief Executive Officer

“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”

John Shannon, Chairman and Chief Executive Officer
4:59 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock

Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).

Value
$51.2K
Shares
5,000
Price
$10.23
Holding change
-0.4%
Trade date
Nov 2, 2026
4:58 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock

Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).

Value
$256K
Shares
25,000
Price
$10.23
Holding change
-2.2%
Trade date
Nov 2, 2026
4:57 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock

Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).

Value
$153K
Shares
15,000
Price
$10.23
Holding change
-0.9%
Trade date
Nov 2, 2026
8:06 AM ET 8-K
Executive Compensation

Xeris Biopharma Holdings Executive Compensation

Xeris Biopharma Holdings appointed Menassie Taddese to its Board of Directors and Audit Committee, effective November 2, 2026. In connection with his appointment, Mr. Taddese received an initial equity award of options and RSUs with a grant date fair value of approximately $450,000 and will be eligible for annual equity grants of $300,000. Mr. Taddese brings nearly 30 years of experience from leadership roles at Viatris and Pfizer.

Counterparty
Menassie Taddese

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.